• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Letter to Shareholders – February 2021

February 10, 2021 By Celyad Oncology

Dear Shareholder,


As I reflect on the past year, I’m proud of our team’s dedication to advancing the Company’s goals while facing head-on the challenges associated with the COVID-19 global pandemic. Our team’s commitment has truly been unparalleled during this time.

Despite these unprecedented times, I firmly believe this was a pivotal year in our Company’s history as we worked to further unlock the full potential of allogeneic CAR T therapy with learnings that we will take into 2021.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use